NTRK2 and neuroleptic malignant syndrome: In this study, we hypothesized that ANA‐12, an antagonist of TrkB, could be a candidate therapeutic agent for visceral hypersensitivity through the inhibition of BDNF/TrkB/PKMζ signalling in NMS rats.